In the wake of Apple’s bombshell announcement of its HealthKit health information platform, Maryland-based glucometer implant company Senseonics says it’s taken another $20 million in funding.
The company says it will use the new money for “the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system.”
Existing Senseonics investors Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, and New Enterprise Associates led the funding round.
Senseonics intends to use the proceeds to continue its product development initiatives, including completing clinical trials in Europe and the U.S.
Diabetes affects an estimated 371 million worldwide. Monitoring glucose levels is essential to managing the disease and avoiding its debilitating complications.